Form 4: Halozyme CEO Exercises, Sells Shares Under 10b5-1 Plan

Halozyme Therapeutics CEO Helen Torley executed pre-planned transactions in early October 2025, exercising stock options and subsequently selling 60,000 common shares.

Summary

• Helen Torley, President and CEO, and a Director of Halozyme Therapeutics, Inc. (HALO), reported transactions involving the company's common stock and derivative securities.
• Between October 1 and October 3, 2025, Torley exercised stock options to acquire a total of 60,000 shares of common stock at an exercise price of $8.11 per share.
• Concurrently, on the same dates, Torley sold all 60,000 shares of common stock acquired from the option exercises at weighted average prices ranging from $68.472 to $75.693 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 21, 2025.
• The sales represent shares acquired from stock options with a ten-year term expiring in February 2026.
• Following these transactions, Torley's direct beneficial ownership of common stock remained at 733,719 shares.
• Her beneficial ownership of derivative securities (options to purchase common stock) decreased from an implied 136,569 options to 76,569 options after the exercises.

Sentiment

Score: 5

Explanation: The transactions are routine insider sales executed under a pre-arranged 10b5-1 plan, primarily driven by the exercise of expiring stock options, which is a common practice for executives to manage their equity compensation. It does not signal a change in company fundamentals or management's outlook.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled and not based on new, non-public information.
• The exercise of options at $8.11 and subsequent sale at significantly higher prices (ranging from $68.472 to $75.693) represents a substantial profit for the insider, reflecting value creation for long-term option holders.
• The sales were primarily driven by the impending expiration of stock options in February 2026, a common and routine practice for executives to monetize their equity compensation.

Negatives

• The sale of 60,000 shares by a key executive, even if pre-planned, could be perceived negatively by some investors as a reduction in direct equity exposure.

Risks

• No specific risks related to the company's operations or financial health were mentioned in this transactional filing.

Future Outlook

This Form 4 filing is purely transactional and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The options exercised and sales reported were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025, in accordance with Rule 10b5-1.
• The sales of common shares represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.

Industry Context

Insider transactions, particularly those involving the exercise of expiring stock options and subsequent sales under a Rule 10b5-1 plan, are common occurrences in the biotechnology and pharmaceutical industries. These transactions are typically part of an executive's long-term compensation strategy and do not usually signal a change in the company's operational fundamentals or strategic direction.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider transactions is a standard corporate governance practice, widely adopted across industries, including biotechnology, to mitigate concerns about trading on material non-public information.
• The exercise of stock options nearing their expiration date and subsequent sale of shares is a routine financial management activity for executives across publicly traded companies, comparable to practices seen at peers like Amgen, Gilead Sciences, or Biogen, where executives regularly manage their equity compensation.

Stakeholder Impact

• Shareholders: The transactions are routine and pre-planned, so they are unlikely to have a significant direct impact on shareholder value or perception beyond the normal course of insider activity.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company were mentioned in this transactional filing.

Key Dates

Recommendation

The transactions represent routine insider activity under a pre-arranged 10b5-1 plan, primarily to exercise expiring stock options and monetize a portion of the resulting shares. This type of transaction is common for executives and does not typically indicate a change in the company's fundamental prospects or management's confidence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an investment thesis.

Keywords

Halozyme Therapeutics, HALO, Helen Torley, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, CEO, Director, Equity Compensation, Stock Sale